Results of toxicology studies with MPC-3100, an oral HSP90 inhibitor.

e13016 Background: MPC-3100, an orally bioavailable synthetic inhibitor of HSP90, has demonstrated efficacy in animal models and is currently in a phase I clinical study in cancer patients. Toxicol...